COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02090933
Recruitment Status : Completed
First Posted : March 19, 2014
Last Update Posted : December 29, 2016
Information provided by (Responsible Party):
National Cancer Institute (NCI)

Brief Summary:
This clinical trial studies celecoxib in decreasing the damaging effects of sunburn in healthy volunteers. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in healthy volunteers.

Condition or disease Intervention/treatment Phase
No Evidence of Disease Drug: Celecoxib Other: Laboratory Biomarker Analysis Procedure: UV Light Therapy Phase 2

Detailed Description:


I. Quantify changes in the erythema response in human subjects exposed to a range of erythemic doses of solar-simulated ultraviolet light before and after celecoxib treatment.

II. Collect blood for genetic analysis of markers likely to modulate erythema response. This includes cyclooxygenase (COX), prostaglandin receptor, P53 and excision-repair polymorphisms.


Participants undergo ultraviolet (UV)-irradiation to the right buttock at baseline, receive celecoxib orally (PO) twice daily (BID) for 10 days, and then undergo UV-irradiation to the left buttock. Chromameter readings are obtained 24 hours post UV-irradiation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Clinical Protocol for an Open Label Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation
Study Start Date : March 2004
Actual Primary Completion Date : December 2004
Actual Study Completion Date : December 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sun Exposure
Drug Information available for: Celecoxib

Arm Intervention/treatment
Experimental: Treatment (celecoxib)
Participants undergo UV-irradiation to the right buttock at baseline, receive celecoxib PO BID for 10 days, and then undergo UV-irradiation to the left buttock.
Drug: Celecoxib
Given PO
Other Name: SC-58635

Other: Laboratory Biomarker Analysis
Correlative studies

Procedure: UV Light Therapy
Undergo UV-irradiation
Other Names:
  • Light Therapy, UV
  • Therapy, UV Light
  • Ultraviolet Radiation Therapy

Primary Outcome Measures :
  1. Changes in the erythema response in human subjects exposed to a range of erythemic doses of solar-simulated ultraviolet light before and after celecoxib treatment [ Time Frame: Baseline up to day 11 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • The subject has Fitzpatrick skin type I, II, or III
  • If the subject is female and of childbearing potential (women are considered not of childbearing potential if they are at least 2 years post-menopausal and/or surgically sterile):

    • Has been using adequate contraception (e.g., condom, intrauterine device [IUD], diaphragm and spermicide gel combination) since her last menses and will use adequate contraception during the study, and
    • Is not lactating, and
    • Will begin taking study drug beginning 2 days after onset of menses
  • The subject is willing to abstain from the use of other non-steroidal anti-inflammatory drugs (NSAIDs) for the duration of the study
  • The subject is willing to abstain from the use of all topical agents applied to the buttocks for the duration of the study with the exception of lotion
  • The subject is willing to participate for the duration of the study
  • The subject has provided written informed consent prior to administration of any study related procedures

Exclusion Criteria:

  • The subject is currently taking any medication that may alter the sunlight response or cause an adverse reaction
  • The subject has a history of melanoma, lupus, psoriasis, rosacea, porphyria, photosensitivity disorder, connective tissue disorder, or any disease that would increase the risk associated with study participation
  • The study has excessive hair, blemishes, nevi, uneven pigmentation, sunburn or suntan on the buttocks
  • The subject has sun bathed or used a tanning bed to expose the buttocks within 12 months of admission to the study
  • The subject has inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), a chronic or acute renal or hepatic disorder or a significant coagulation defect or any other condition which in the Investigator's opinion might preclude use of an NSAID (e.g., congestive heart failure)
  • The subject has an active malignancy of any type; subjects who have a history of nonmelanoma skin cancer and have been treated are acceptable; subjects with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years prior to study enrollment are also acceptable
  • The subject has active or suspected peptic ulceration or gastrointestinal bleeding
  • The subject has received any investigational medication within 30 days prior to the first dose of study medication or is scheduled to receive an investigational drug other than celecoxib during the course of this study
  • The subject has a known hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, or NSAIDs
  • The subject has significant medical or psychosocial problems that would make the subject a poor candidate, in the opinion of the principal investigator
  • The subject is currently taking celecoxib

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02090933

Layout table for location information
United States, New York
University of Rochester
Rochester, New York, United States, 14642
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Alice Pentland University of Rochester
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT02090933    
Other Study ID Numbers: NCI-2014-00524
NCI-2014-00524 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
RSRB#10077 ( Other Identifier: University of Rochester )
N01-CN-85183-Step-1-Ext ( Other Identifier: DCP )
N01CN85183 ( Other Identifier: US NIH Grant/Contract Award Number )
First Posted: March 19, 2014    Key Record Dates
Last Update Posted: December 29, 2016
Last Verified: December 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action